Volume 7, Issue 2 (7-2019)                   Jorjani Biomed J 2019, 7(2): 61-70 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

ajam F, Aghaei M, Mohammadi S, Saeedi M, Behnampour N, Memarian A. Increased expression of PD-1 on CD4+ T cells subsets in Rheumatoid Arthritis patients. Jorjani Biomed J. 2019; 7 (2) :61-70
URL: http://goums.ac.ir/jorjanijournal/article-1-664-en.html
1- Student Research Committee, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran
2- Golestan Rheumatology Research Center (GRRC), Golestan University of Medical Sciences, Gorgan, Iran
3- Stem Cell Research Center, Golestan University of Medical Sciences, Gorgan, Iran
4- Public Health Department, Faculty of Health, Golestan University of Medical Sciences, Gorgan, Iran
5- Golestan Rheumatology Research Center (GRRC), Golestan University of Medical Sciences, Gorgan, IranGolestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Sciences, Gorgan, Iran , alimemarian@goums.ac.ir
Abstract:   (326 Views)
Study objectives: Rheumatoid arthritis (RA) is a common chronic and systemic autoimmune disease, characterized by inflammation and the destruction of the joints. It is well known that CD4+ T cells play a major role in the pathogenesis of RA. Expanded subpopulations of CD4+ T cells have been reported in RA patients. Here, we investigated the expression of PD-1 on subsets of CD4+ T cells (CD4+CD28- and CD4+CD28+ T cells) in the peripheral blood (PB) and synovial fluid (SF) of patients with RA.
Methods: A total of 42 RA patients, including 10 newly diagnosed (ND) and 32 relapsed (RL) cases and also 20 healthy controls were enrolled. Phenotypic characterization subsets of CD4+ T cells were evaluated by flow cytometry, using fluorescence conjugated specific human monoclonal antibodies.
Results: The frequency of CD4+CD28+ T cells was significantly increased in SF versus PB in ND and RL patients. In contrast, the percentage of CD4+CD28- T cells was elevated in PB of ND and RL patients comparison to SF. Expression of PD-1 on CD4+CD28+ and CD4+CD28- T cells in PB of ND and RL patients was significantly higher than the healthy controls. Furthermore, PD-1 expression on CD4+CD28+ and CD4+CD28- T cells in SF versus PB of RL patients were significant increased.
Conclusion: These data suggest that CD4+ T cells subsets in RA patients were resistance to PD-1 mediated effects and PD-1 has insufficient ability to suppression of CD4+T cells.
Full-Text [PDF 416 kb]   (112 Downloads)    
Type of Article: Original article | Subject: Basic Medical Sciences
Received: 2019/09/28 | Revised: 2020/01/27 | Accepted: 2019/10/7

References
1. García‐Vicuña R, Gómez‐Gaviro MV, Domínguez‐Luis MJ, Pec MK, González‐Alvaro I, Alvaro‐Gracia JM, et al. CC and CXC chemokine receptors mediate migration, proliferation, and matrix metalloproteinase production by fibroblast‐like synoviocytes from rheumatoid arthritis patients. Arthritis & Rheumatism. 2004;50(12):3866-77. [DOI:10.1002/art.20615]
2. Lin SC, Yen JH, Tsai JJ, Tsai WC, Ou TT, Liu HW, et al. Association of a programmed death 1 gene polymorphism with the development of rheumatoid arthritis, but not systemic lupus erythematosus. Arthritis & Rheumatism. 2004;50(3):770-5. [DOI:10.1002/art.20040]
3. Li S, Liao W, Chen M, Shan S, Song Y, Zhang S, et al. Expression of programmed death-1 (PD-1) on CD4+ and CD8+ T cells in rheumatoid arthritis. Inflammation. 2014;37(1):116-21. [DOI:10.1007/s10753-013-9718-8]
4. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 2000;43(2):250-8. [DOI:10.1002/1529-0131(200002)43:23.0.CO;2-P]
5. Gracie JA, Forsey RJ, Chan WL, Gilmour A, Leung BP, Greer MR, et al. A proinflammatory role for IL-18 in rheumatoid arthritis. The Journal of clinical investigation. 1999;104(10):1393-401. [DOI:10.1172/JCI7317]
6. Janossy G, Duke O, Poulter L, Panayi G, Bofill M, Goldstein G. Rheumatoid arthritis: a disease of T-lymphocyte/macrophage immunoregulation. The Lancet. 1981;318(8251):839-42. [DOI:10.1016/S0140-6736(81)91107-7]
7. Zhang X, Nakajima T, Goronzy JJ, Weyand CM. Tissue trafficking patterns of effector memory CD4+ T cells in rheumatoid arthritis. Arthritis & Rheumatism. 2005;52(12):3839-49. [DOI:10.1002/art.21482]
8. Herman S, Zurgil N, Langevitz P, Ehrenfeld M, Deutsch M. The immunosuppressive effect of methotrexate in active rheumatoid arthritis patients vs. its stimulatory effect in nonactive patients, as indicated by cytometric measurements of CD4+ T cell subpopulations. Immunological investigations. 2004;33(3):351-62. [DOI:10.1081/IMM-120039865]
9. Pieper J, Johansson S, Snir O, Linton L, Rieck M, Buckner JH, et al. Peripheral and Site‐Specific CD 4+ CD 28null T Cells from Rheumatoid Arthritis Patients Show Distinct Characteristics. Scandinavian journal of immunology. 2014;79(2):149-55. [DOI:10.1111/sji.12139]
10. Strickland FM, Patel D, Khanna D, Somers E, Robida AM, Pihalja M, et al. Characterisation of an epigenetically altered CD4+ CD28+ Kir+ T cell subset in autoimmune rheumatic diseases by multiparameter flow cytometry. Lupus science & medicine. 2016;3(1):e000147. [DOI:10.1136/lupus-2016-000147]
11. Bartosińska J, Zakrzewska E, Krol A, Raczkiewicz D, Purkot J, Majdan M, et al. Differential expression of programmed death 1 (PD-1) on CD4+ and CD8+ T cells in rheumatoid arthritis and psoriatic arthritis. Polish archives of internal medicine. 2017;127(12):815-22. [DOI:10.20452/pamw.4137]
12. Wan B, Nie H, Liu A, Feng G, He D, Xu R, et al. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. The Journal of Immunology. 2006;177(12):8844-50. [DOI:10.4049/jimmunol.177.12.8844]
13. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham III CO, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis & Rheumatism. 2010;62(9):2569-81. [DOI:10.1002/art.27584]
14. Mohammadi S, Memarian A, Sedighi S, Behnampour N, Yazdani Y. Immunoregulatory effects of indole-3-carbinol on monocyte-derived macrophages in systemic lupus erythematosus: a crucial role for aryl hydrocarbon receptor. Autoimmunity. 2018;51(5):199-209. [DOI:10.1080/08916934.2018.1494161]
15. Bryl E, Vallejo AN, Matteson EL, Witkowski JM, Weyand CM, Goronzy JJ. Modulation of CD28 expression with anti-tumor necrosis factor α therapy in rheumatoid arthritis. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 2005;52(10):2996-3003. [DOI:10.1002/art.21353]
16. Namekawa T, Wagner UG, Goronzy JJ, Weyand CM. Functional subsets of CD4 T cells in rheumatoid synovitis. Arthritis & Rheumatism. 1998;41(12):2108-16. [DOI:10.1002/1529-0131(199812)41:123.0.CO;2-Q]
17. Warrington KJ, Takemura S, Goronzy JJ, Weyand CM. CD4+, CD28− T cells in rheumatoid arthritis patients combine features of the innate and adaptive immune systems. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 2001;44(1):13-20. [DOI:10.1002/1529-0131(200101)44:13.0.CO;2-6]
18. Schmidt D, Goronzy JJ, Weyand CM. CD4+ CD7-CD28-T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity. The Journal of clinical investigation. 1996;97(9):2027-37. [DOI:10.1172/JCI118638]
19. El-Menoufy MA, El-Kak AE-AA, Ahmed MA. Unusual CD4+ CD28− T lymphocyte subset is implicated in the pathogenesis of early atherosclerosis in patients with rheumatoid arthritis. The Egyptian Rheumatologist. 2019;41(2):105-9. [DOI:10.1016/j.ejr.2018.06.003]
20. Pawłowska J, Mikosik A, Soroczynska-Cybula M, Jóźwik A, Łuczkiewicz P, Mazurkiewicz S, et al. Different distribution of CD4 and CD8 T cells in synovial membrane and peripheral blood of rheumatoid arthritis and osteoarthritis patients. Folia Histochemica et Cytobiologica. 2009;47(4):627-32. [DOI:10.2478/v10042-009-0117-9]
21. Fasth AE, Snir O, Johansson AA, Nordmark B, Rahbar A, af Klint E, et al. Skewed distribution of proinflammatory CD4+ CD28 null T cells in rheumatoid arthritis. Arthritis research & therapy. 2007;9(5):R87. [DOI:10.1186/ar2286]
22. Bommarito D, Hall C, Taams L, Corrigall V. Inflammatory cytokines compromise programmed cell death‐1 (PD‐1)‐mediated T cell suppression in inflammatory arthritis through up‐regulation of soluble PD‐1. Clinical & Experimental Immunology. 2017;188(3):455-66. [DOI:10.1111/cei.12949]
23. Raptopoulou AP, Bertsias G, Makrygiannakis D, Verginis P, Kritikos I, Tzardi M, et al. The programmed death 1/programmed death ligand 1 inhibitory pathway is up‐regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis. Arthritis & Rheumatism. 2010;62(7):1870-80. [DOI:10.1002/art.27500]
24. Liu C, Jiang J, Gao L, Wang X, Hu X, Wu M, et al. Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways. Arthritis research & therapy. 2015;17(1):340. [DOI:10.1186/s13075-015-0859-z]
25. Luo Q, Ye J, Zeng L, Luo Z, Deng Z, Li X, et al. Elevated expression of PD‑1 on T cells correlates with disease activity in rheumatoid arthritis. Molecular medicine reports. 2018;17(2):3297-305. [DOI:10.3892/mmr.2017.8204]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


© 2020 All Rights Reserved | Jorjani Biomedicine Journal

Designed & Developed by : Yektaweb